NCAA "March Madness" is about to begin, with Duke University currently having the highest probability of winning the championship on Polymarket.
NCAA "March Madness" will officially kick off on March 18, with 68 universities across the United States competing for the championship through a single-elimination format.
Polymarket's real-time probabilities currently show the top four universities in championship odds as follows: Duke University, which features next season's NBA top draft prospect Cameron Boozer, ranks first with 21%; traditional powerhouse Michigan University ranks second with 18%; Arizona University ranks third with 17%; and defending champion Florida University ranks fourth with 11%.
Odaily note: NCAA "March Madness" refers to the National Championship of the NCAA Division I Men's Basketball Tournament. This event usually starts every March, adopts a single-elimination format, and features a dense schedule and fierce competition, hence the name "March Madness".
Keep a close eye on prediction markets—see the changes before the pricing.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Crypto prices
More
